Michael Serzan: Kidney Clinical Science Symposium at ASCO25
Michael Serzan, Genitourinary Medical Oncologist at Dana Farber Cancer Institute, shared a post on X:
“Kidney Clinical Science Symposium ASCO25
Abs4511: Dr David Braun presenting analysis of circulating blood and tumor microenvironment for response to Cabo/Nivo on CheckMate9ER.
Clinical implications:
- Cabo/Nivo responses enriched in TME with high VICM anti-tumor macrophage), high PD-L1, high plasma, and low circulating Treg
Further Reading
Biomarker-informed care for patients with renal cell carcinoma by Mackenzie McKinnon and Scott Haake
n = 150 (23% of ITT)
- PD-L1 staining
- 4 PBMC markers
- 4 ECM markers
- 7 HnE HIF features.
ECM marker VICM (fragment of vimentin measures macrophage activity and immune status) was prognostic across both therapies.
Log regression models that integrated highly informatic features had AUCs of 0.76 for NIVO+CABO model and 0.72 for the SUN model.
NIVO+CABO arm determinants of response
- high VICM (anti-tumor macrophage polarization)
- high PD-L1
- high plasma cell
- high cancer cell at the epithelial stromal interface
- low circulating (Pro-C6)
- low % circulating Treg (Foxp3+ CD4+)”
More posts featuring Michael Serzan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023